Promising Alzheimer’s Drug Trial Results from BiogenMarch 26th, 2015
Above: Amyloid plaques in the brain of an Alzheimer’s patient.
As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s disease. The drug, aducanumab, lowered brain Abeta levels and slowed decline in cognitive function compared to a control group of Alzheimer’s patients receiving a placebo.
Read more about these exciting results and what they mean for the future of Alzheimer’s drug development.